Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.


Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Drent E, Poels R, Mulders MJ, van de Donk NWCJ, Themeli M, Lokhorst HM, Mutis T.

PLoS One. 2018 May 30;13(5):e0197349. doi: 10.1371/journal.pone.0197349. eCollection 2018.


CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.

Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Review.


A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T.

Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.


Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.

Themeli M, Sadelain M.

Trends Mol Med. 2016 Apr;22(4):271-273. doi: 10.1016/j.molmed.2016.02.009. Epub 2016 Mar 10.


Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T.

Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.


Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene.

Kotini AG, de Stanchina E, Themeli M, Sadelain M, Papapetrou EP.

Mol Ther Nucleic Acids. 2016 Feb 2;5:e284. doi: 10.1038/mtna.2015.57.


New cell sources for T cell engineering and adoptive immunotherapy.

Themeli M, Rivière I, Sadelain M.

Cell Stem Cell. 2015 Apr 2;16(4):357-66. doi: 10.1016/j.stem.2015.03.011. Review.


The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells.

Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD.

Stem Cell Reports. 2015 Apr 14;4(4):658-69. doi: 10.1016/j.stemcr.2015.02.003. Epub 2015 Mar 5.


PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Fedorov VD, Themeli M, Sadelain M.

Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.


Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.

Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M.

Nat Biotechnol. 2013 Oct;31(10):928-33. doi: 10.1038/nbt.2678. Epub 2013 Aug 11.


DNA damage and repair in epithelium after allogeneic hematopoietic stem cell transplantation.

Themeli M, Spyridonidis A.

Int J Mol Sci. 2012 Nov 27;13(12):15813-25. doi: 10.3390/ijms131215813. Review.


Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites.

Lazana I, Zoudiari A, Kokkinou D, Themeli M, Liga M, Papadaki H, Papachristou D, Spyridonidis A.

Haematologica. 2012 Sep;97(9):1338-47. doi: 10.3324/haematol.2011.055871. Epub 2012 Mar 14.


DNA chimerism and its consequences after allogeneic hematopoietic cell transplantation.

Themeli M, Waterhouse M, Finke J, Spyridonidis A.

Chimerism. 2011 Jan;2(1):25-8. doi: 10.4161/chim.2.1.15276.


Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia.

Spyridonidis A, Liga M, Triantafyllou E, Themeli M, Marangos M, Karakantza M, Zoumbos N.

Bone Marrow Transplant. 2011 Oct;46(10):1363-8. doi: 10.1038/bmt.2010.308. Epub 2010 Dec 20.


Horizontal DNA transfer from donor to host cells as an alternative mechanism of epithelial chimerism after allogeneic hematopoietic cell transplantation.

Waterhouse M, Themeli M, Bertz H, Zoumbos N, Finke J, Spyridonidis A.

Biol Blood Marrow Transplant. 2011 Mar;17(3):319-29. doi: 10.1016/j.bbmt.2010.09.001. Epub 2010 Sep 15.


Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia.

Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N, Finke J, Spyridonidis A.

Leukemia. 2010 Mar;24(3):536-43. doi: 10.1038/leu.2009.284. Epub 2010 Jan 14.


Horizontal DNA and mRNA transfer between donor and recipient cells after allogeneic hematopoietic cell transplantation?

Waterhouse M, Themeli M, Metaxas Y, Lagadinou ED, Finke J, Spyridonidis A.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2704-13. Review.


Supplemental Content

Loading ...
Support Center